Scarica l'app Stockscreener
8.20
2.76%
0.22
Dopo l'orario di chiusura:
8.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.98
Aprire:
$7.91
Volume 24 ore:
2.30M
Relative Volume:
0.93
Capitalizzazione di mercato:
$742.62M
Reddito:
$30.91M
Utile/perdita netta:
$-209.47M
Rapporto P/E:
-2.464
EPS:
-3.3279
Flusso di cassa netto:
$-147.13M
1 W Prestazione:
+13.57%
1M Prestazione:
+41.14%
6M Prestazione:
+41.14%
1 anno Prestazione:
-22.35%
Intervallo 1D:
$7.72
$8.21
Intervallo di 1 settimana:
$7.00
$8.21
Portata 52W:
$3.43
$11.24
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
8.20 | 617.64M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2026-02-04 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-16 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Verastem Oncology to Participate in Upcoming September Investor Conferences - Business Wire
Verastem Inc. (VSTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform (NASDAQ:VSTM) - Seeking Alpha
Verastem Inc. (VSTM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views - Yahoo Finance
Verastem (VSTM) Watch: Records a 1.03% Increase to $6.89 on the Day; Technical View - vinanet.vn
Verastem (NASDAQ:VSTM) Shares Down 8.6%Should You Sell? - MarketBeat
Verastem (VSTM) Q2 2026 Earnings Call Transcript - AOL.com
VSTM | Verastem, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Verastem (NASDAQ:VSTM) Shares Up 6.4%What's Next? - MarketBeat
Precision Trading with Verastem Inc. (VSTM) Risk Zones - news.stocktradersdaily.com
Verastem (VSTM) Slips 1.35% to $6.58 as Biotech Stock Holds Above Key SupportDebt Free Companies - vinanet.vn
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Verastem (VSTM) Pulls Back 1.42% to $6.58 as Support HoldsOBV Breakout - vinanet.vn
Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital - Stock Titan
Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM - MarketBeat
Verastem Inc (VSTM) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
VSTM Maintains by Mizuho -- Price Target Lowered to $13.00 - GuruFocus
Mizuho lowers Verastem stock price target on valuation to $13 By Investing.com - Investing.com Nigeria
Mizuho lowers Verastem stock price target on valuation to $13 - Investing.com India
Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating - Yahoo Finance
Q2 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Q1 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Weekly Recap: Q2 2026 revenue, cash, losses and RAMP Phase 3 readout - TradingView
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $12 to $18 - Moomoo
Verastem (VSTM) Stock Rallies On Revenue Surge And Pipeline Pressure - Sahm
Verastem Inc (VSTM) Stock News Today - TradingKey
Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Verastem Q2 Earnings Call Highlights - MarketBeat
VSTM Maintained by Guggenheim -- Price Target Lowered to $12.00 - GuruFocus
Verastem Oncology (VSTM) Posts Solid Q2 2026; Market Pricing Ref - GuruFocus
State Street Corporation (VSTM) discloses 5.8% beneficial ownership in INC common stock - Stock Titan
Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Verastem, Inc. Stock 12‑Month Price Target Cut to $14.88, Implies 152% Upside - TradingView
VerastemEnters Amendment No. 3 To Note Purchase Agreement On August 6, 2026SEC Filing - TradingView
Verastem Amends Oberland Financing, Adding Up to $75 Million Revenue-Share Notes Maturing 2033 - TradingView
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong R - GuruFocus
Verastem, Inc. (VSTM) Stock Analysis: 151.69% Potential Upside In Biotech Space - DirectorsTalk Interviews
Verastem Expects Initial Registrational Data for KRAS G12D Inhibitor Cancers This Year - GenomeWeb
How Did Verastem Inc (VSTM) Perform in Q2 2026? Revenue of $40.1 - GuruFocus
Earnings call transcript: Verastem beats Q2 2026 estimates, shares jump after hours - Investing.com
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verastem, Inc. 2026: Revenue $40.08M, EPS ($0.35) — 10-Q Summary - TradingView
VERASTEM ($VSTM) Releases Q2 2026 Earnings - Moomoo
Verastem: Q2 Earnings Snapshot - Barchart.com
Verastem (Nasdaq: VSTM) lifts Q2 2026 revenue to $40M, discloses going‑concern risk - Stock Titan
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):